College of Public Overall health, Imperial College London, Hammersmith Hospital, London, UK 39INSERM U1018, Centre de Recherche en Epid iologie et Santdes Populations (CESP), Villejuif, France 40UniversitParis Sud, UMRS 1018, Villejuif, France 41Institut InterR ional pour la Sant(IRSA), La Riche, France 42Developmental Biochemistry, TheodorBoveriInstitute, Biocenter, University of W zburg, W zburg, Germany 43CHU Nantes, Service de G ique M icale, Nantes, FranceNIHPA Author Manuscript NIHPA Author Manuscript NIHPA Author ManuscriptNat Genet. Author manuscript; available in PMC 2014 September 01.Bezzina et al.PageAcknowledgmentsWe thank L. Beekman, C. de Gierde Vries, B. de Jonge as well as the Genomic Platform of Nantes (Biogenouest Genomics) for technical assistance. We are also grateful to the French Clinical Network against Inherited Cardiac Arrhythmias, which consists of the University Hospitals of Nantes, Bordeaux, Rennes, Tours, Brest, Strasbourg, La R nion, Angers and Montpellier.5-Hydroxymethylfurfural custom synthesis This study was funded by investigation grants in the Leducq Foundation (CVD05; Alliance Against Sudden Cardiac Death), the Ministry of Education, Culture, Sports, Science and Technology of Japan (grantinaid for the Project in Sado for Total Health, PROST), the French Ministry of Health (PHRC AOR04070, P040411 and PHRCI DGS2001/0248), INSERM (ATIPAvenir plan to R.R.) plus the French Regional Council of PaysdelaLoire. This analysis was also supported by the Netherlands Heart Institute (grant 061.02 to C.A.R. and C.R.B.) as well as the Division for Earth and Life Sciences (ALW; project 836.09.003 to C.A.R.) with financial help in the Netherlands Organization for Scientific Investigation (NWO). C.R.B. acknowledges assistance in the Netherlands Heart Foundation (NHS 2007B202 and 2009B066). J.B. was supported by a study grant from the European Society of Cardiology as well as the Netherlands Heart Institute (ICIN) and by the FrenchDutch Academy by means of the Van Gogh system. E.S.B. was supported by the Interdisziplin en Zentrums f Klinische Forschung (IZKF) of your University of M ster along with the Collaborative Research Center SFB656. M.G. acknowledges help from the German Investigation Foundation (DFGSFB 688 and TP A16). This manuscript is devoted towards the memory of Denis Escande, who founded the Leducq Foundation Network Alliance Against Sudden Cardiac Death.2089377-51-3 site NIHPA Author Manuscript NIHPA Author Manuscript NIHPA Author Manuscript
As lots of as 30 of male survivors of cancer in childhood and young adulthood are at danger of sterility as a result of therapy with highdose chemotherapy, totalbody irradiation, or irradiation with scatter to the genital region (Thomson et al.PMID:33495303 , 2002; Meistrich et al., 2005). Whereas adults possess the selection of cryopreserving semen prior to therapy to ensure that they could generate offspring, prepubertal or peripubertal patients cannot supply acceptable semen sample either as a result of sperm insufficiency or sociological reasons. Thus they don’t at the moment have any fertility preservation possibilities which have proven successful. Development of new methods of fertility preservation to stop these effects or restore normal reproductive function following cytotoxic treatment are of terrific importance to these young male cancer survivors. If spermatogonial stem cells (SSC) survive immediately after cancer therapy, there is the possibility for endogenous spermatogenic recovery either by spontaneous or stimulated differentiation of those cells. Suppression of gonadotropins and testosterone stimulated endogenous recovery of spe.
